IBIO   $6.31  8.61% Market Open

iBio, Inc.
Last Events:

2023-08-09 Signal in Stochastic changed from bullish to bearish. The stochastic indicator is in the lower part of the neutral territory and it heading south. These factors indicate that negative dynamics is recovering. Last signal: main and signal line crossing.

2023-08-09 Signal in RSI changed from bullish to bearish. RSI indicator is in the lower part of the neutral territory and it heading south. These factors indicate that negative dynamics is recovering. Last signal: exit from the overbought zone.

2023-08-09 Signal in EMA20 changed from bullish reversal to bearish reversal. The price is trying to cross down the moving average line If the intersection will be successful, then a downside trend can be formed.

2023-08-06 Signal in Stochastic changed from bullish reversal to bullish. The stochastic indicator is in the upper part of the neutral territory and it grows. These factors indicate that positive dynamics persists. Last signal: up-crossing the middle level.

2023-08-06 Signal in RSI changed from bullish reversal to bullish. RSI indicator is in the upper part of the neutral territory and it grows. These factors indicate that positive dynamics persists. Last signal: entrance to the overbought zone.

2023-08-06 Signal in EMA20 changed from bearish reversal to bullish reversal. The price is trying to cross up the moving average line If the intersection will be successful, then an upside trend can be formed.

2023-08-05 Signal in RSI changed from bearish recovery to bullish reversal. RSI indicator is in the lower part of the neutral territory and left the oversold territory. These factors indicate that perhaps the downside trend is coming to an end price will probably head north Last signal: exit from the overbought zone.

2023-08-03 Signal in RSI changed from bullish reversal to bearish recovery. RSI indicator is in the oversold territory and it heading south. These factors indicate that the downside potential still holds even though the market is oversold. Last signal: exit from the overbought zone.


Current temperature: 4.25
ST: 0, Cor:

50-50 Year Forecast
Low with % probability:
Target: 3.69
High with % probability:
Analyst Recommendations:
Number of estimates 3
Target Price Mean 4.8667
Mean unverified/preliminary 4.8667 / 4.8667
Target Price Low / High 3.6000 / 6.0000
Median / STD DEV 5.0000 / 1.21
Tech Forecasts:
More signals
  < 1M 1-3M > 3M
total Buy Sell ActivelyBuy
rsi Buy Sell ActivelyBuy
macd None ActivelyBuy None
stoch None None None
ma20 Sell Sell Sell
ma50 None None None
ma100 None Sell None
Candlestick PatternFeb. 11, 2025 Bearish Three Outside Down - pattern is a made up of three candlesticks. A white candlestick appears on the first day in a uptrend. The second day body engulfs the white body of the first day. A black candlestick on the third day with a lower close than the second day. Considered to be a bearish reversal pattern.
ISIN US4510337086
ceo Dr. Martin B. Brenner D.V.M., Ph.D.
Website https://ibioinc.com
iBio, Inc., a preclinical stage biotechnology company, engages in the development of artificial intelligence (AI) antibodies solutions for cancer, and other diseases. The company's technology platforms include EngageTx that provides improved CD3 T-cell engager antibody panel; ShieldTx, an antibody masking technology that enables the creation of conditionally activated antibodies; StableHu, an AI antibody-optimizing technology; and AI epitope steering technology that guides antibodies against the desired regions of the target protein. Its product pipelines for cardiometabolic disease area include IBIO-101, an anti-CD25 Mab that binds and depletes immunosuppressive regulatory treg cells to inhibit the growth of solid tumors; CCR8, an antibody that enhance the body's immune response against cancer cells; and trophoblast cell surface antigen 2, a monoclonal antibodies, as well as MUC16 and Target 5 antibodies. In addition, the company is developing EGFRvIII, an antibody therapeutics that targets EGFRvIII protein with the aim to address these cancer types without affecting healthy cells. It has a collaboration agreement with AstralBio to discover and develop novel antibodies for obesity and other cardiometabolic diseases. iBio, Inc. was incorporated in 2008 and is headquartered in San Diego, California.